1531 GMT - Novo Nordisk's trial of CagriSema in obese patients with diabetes demonstrated 13.7% weight loss, below investor expectations of around 15% and broadly in line with Eli Lilly's Zepbound drug, Bank of America Securities analysts Sachin Jain and Graham Parry write. The drug had already disappointed in a trial of patients without diabetes. The bank had seen potential for CagriSema to demonstrate superior weight loss to Zepbound, but the difference between the drug's effect on obese patients and obese diabetic patients looks very similar to both Novo Nordisk's current Semaglutide drug and Zepbound. The data therefore unlikely changes the CagriSema debates around commercial positioning and its insufficient differentiation versus high-dose Semaglutide, among others, they say. Shares fall 2.9%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 11, 2025 11:31 ET (15:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。